Clearmind Medicine featured in "Psychedelics Tonight," streaming on ALTRD.TV

Clearmind Medicine featured in “Psychedelics Tonight,” streaming on ALTRD.TV

The first episode, “Psychedelic Novelty – Before it was Cool”, presents the exclusive molecule of the company MEAI

VANCOUVER, Oct. 11, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“clear mind“or the”company“), a biotechnology company focused on the discovery and development of new psychedelic-derived therapies to solve major undertreated health problems, is featured on “Psychedelics Tonight,” a new show exploring the life-changing benefits of psychedelic drugs, which airs on ALTRD .TV, one of the leading alternative content television networks.

Now available to watchthe 3rd show episode, “Psychedelic Novelty – Before It Was Cool”, presents MEAI, Clearmind’s proprietary molecule, the science behind it, its mechanism of action and the potential to help people with alcohol use disorders. The 4e episode, also featuring MEAI, “New Drugs – Undiscovered Psychedelics” broadcast on October 17 on the channel, which is available on iOS app, AppleTV, GoogleTV, google play application and store.

Psychedelics Tonight is a show about paradigm shifting ideas about the power and potential of psychedelics to benefit people. The show was created by Kyle Buller and Joe Moore, who are also the co-founders of Psychedelics Today. The Company contributed to the production costs of these two episodes of the show.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of novel psychedelic-derived therapies to address widespread and underserved health conditions, including alcohol use disorders. Its main focus is to research and develop psychedelic-based compounds and attempt to market them as regulated drugs, foods, or supplements.

The Company’s intellectual portfolio currently consists of seven patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic in acquiring additional intellectual property to build its portfolio.

Clearmind’s shares are listed on the Canadian Securities Exchange under the symbol “ID card“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC Markets under the symbol “CMNDF“.

For more information, please contact:

Investor Relations,

Email: invest@clearmindmedicine.com

Phone: (604) 260-1566

General Information,

Info@Clearmindmedicine.com

www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This press release may contain forward-looking statements and information based on current expectations. These statements should not be construed as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those implied by such statements. These representations include submitting relevant documentation in a timely manner to the satisfaction of the relevant regulatory authorities and raising sufficient funding to carry out the Company’s business strategy. There is no certainty that any of these events will occur. Although these statements are based on management’s reasonable assumptions, there can be no assurance that these assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing in early-stage companies inherently involves a high degree of risk, and an investment in securities of the Company should be considered highly speculative.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of the securities in any province where such offer, solicitation or sale would be unlawful. The securities issued or to be issued under the Private Placement have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States in the United States. lack of registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the CSE policies) accepts responsibility for the adequacy or accuracy of this release.

#Clearmind #Medicine #featured #Psychedelics #Tonight #streaming #ALTRD.TV

Leave a Comment

Your email address will not be published. Required fields are marked *